These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18955446)

  • 1. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.
    Hurria A; Wong FL; Villaluna D; Bhatia S; Chung CT; Mortimer J; Hurvitz S; Naeim A
    J Clin Oncol; 2008 Nov; 26(33):5386-92. PubMed ID: 18955446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.
    Hurria A; Wong FL; Pal S; Chung CT; Bhatia S; Mortimer J; Somlo G; Hurvitz S; Villaluna D; Naeim A
    Oncologist; 2009 Sep; 14(9):883-90. PubMed ID: 19726455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
    Hurria A; Naeim A; Elkin E; Limaye S; Grover A; Hudis C; Pearce C; Robson M
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):255-60. PubMed ID: 17098441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.
    Naeim A; Wong FL; Pal SK; Hurria A
    Clin Breast Cancer; 2010 Apr; 10(2):136-43. PubMed ID: 20353934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment recommendations for older women with breast cancer: A survey among surgical, radiation and medical oncologists.
    Hamelinck VC; Stiggelbout AM; van de Velde CJH; Liefers GJ; Bastiaannet E
    Eur J Surg Oncol; 2017 Jul; 43(7):1288-1296. PubMed ID: 28258786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty.
    Wasif N; Ye X; Giuliano AE
    Ann Surg Oncol; 2009 Sep; 16(9):2442-9. PubMed ID: 19506955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
    Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
    Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of primary and metastatic triple negative breast cancer: perceptions of oncologists from India.
    Parikh PM; Gupta S; Parikh B; Smruti BK; Issrani J; Topiwala S; Goswami C; Bhattacharya GS; Sen T; Sekhon JS; Malhotra H; Nag S; Chacko RT; Govind KB; Raja T; Vaid AK; Doval DC; Gupta S; Das PK
    Indian J Cancer; 2011; 48(2):158-64. PubMed ID: 21768659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
    Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
    Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
    J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy and differential invasive breast cancer specific survival in elderly women.
    Kaplan HG; Malmgren JA; Atwood MK
    J Geriatr Oncol; 2013 Apr; 4(2):148-56. PubMed ID: 24071540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 status in elderly women with breast cancer.
    Laird-Fick HS; Gardiner JC; Tokala H; Patel P; Wei S; Dimitrov NV
    J Geriatr Oncol; 2013 Oct; 4(4):362-7. PubMed ID: 24472480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
    Martín M; González-Rivera M; Morales S; de la Haba-Rodriguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; Prat A
    Curr Med Res Opin; 2015 Jun; 31(6):1129-37. PubMed ID: 25851308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.